WuXi AppTec to sell research units to Hillhouse

31 October 2025

China’s R&D and manufacturing services provider WuXi AppTec (SHA: 603259) has reached agreement for Hillhouse Investment Management to acquire WuXi AppTec’s China-based clinical research services business, including WuXi Clinical, a Clinical Contract Research Organization (CRO), and WuXi MedKey, a Site Management Organization (SMO).

Financial details of the sale were not disclosed. WuXi announced the news on the same day it released its financial results for the first three quarters of 2025, which showed year-over-year total revenue up 18.6% to 32.86 billion renminbi ($4.62 billion).

Strategically divesting the clinical research services business allows WuXi AppTec to further invest in and strengthen its core Contract Research, Development, and Manufacturing Organization (CRDMO) platform. This builds on the company’s legacy of exceptional drug discovery, laboratory testing, process development and manufacturing services, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK